Balyasny Asset Management
TARA icon

Balyasny Asset Management’s Protara Therapeutics TARA Stock Holding History

Balyasny Asset Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,710
Closed -$79.7K – 3333
2025
Q1 		$79.7K Buy
+18,710
New +$83.6K ﹤0.01% 2696

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Balyasny Asset Management's TARA Position: Q2 2025 in Review

Balyasny Asset Management sold out of Protara Therapeutics (TARA) in Q2 2025, closing a stake of 18,710 shares — an estimated $79.7K sold.

Balyasny Asset Management first reported a position in TARA in Q1 2025 and held it in 1 quarter. The position peaked at $79.7K in Q1 2025. 76 funds tracked by Wall St. Rank hold TARA as of Q2 2025.

  • Balyasny Asset Management reported no remaining Protara Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 18,710 Protara Therapeutics shares in Q2 2025, an estimated $79.7K.
  • Balyasny Asset Management first reported a position in Protara Therapeutics in Q1 2025 and held it in 1 quarter.
  • Balyasny Asset Management's Protara Therapeutics position peaked at $79.7K in Q1 2025.
  • 76 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.